Apitegromab: Scholar Rock's Myostatin Drug for SMA

The drug everyone thought was dead. Apitegromab is the first myostatin-targeted antibody to read out positive Phase 3 data in spinal muscular atrophy, and the FDA accepted its application after a manufacturing setback in 2024.

It does something earlier myostatin drugs could not. By grabbing the inactive precursor of myostatin instead of the active protein, apitegromab avoids the bleeding side effects that sank ACE-031 and stamulumab.

What apitegromab actually does

It does not block active myostatin. Apitegromab is a fully human IgG4 monoclonal antibody that selectively binds promyostatin and latent myostatin, the inactive precursors stored in muscle.

By neutralizing the latent pool, the drug reduces how much mature myostatin gets activated at the muscle surface. That keeps the muscle-growth brake from being applied as hard.

Lab work confirms the selectivity. The antibody does not bind active myostatin, activin A, active BMP9 or BMP10, or TGF-β1, which is the structural reason it does not reproduce the telangiectasia and epistaxis problems that stopped ACE-031 in Duchenne trials.

That selectivity is the whole story for why apitegromab survived where earlier myostatin programs failed.

Why SMA needs a muscle drug at all

SMN therapies fixed half the problem. Nusinersen (Spinraza) and risdiplam (Evrysdi) raise SMN protein in motor neurons, which slows the neurodegenerative side of spinal muscular atrophy, and onasemnogene abeparvovec (Zolgensma) replaces the gene.

But the muscle damage that already happened does not come back on its own. Kids on SMN therapy still have weak quadriceps, weak trunk muscles, and motor function scores well below their peers.

That gap is what Scholar Rock targeted. If you can rebuild the muscle that has already atrophied, you give the strengthened SMN signaling something to actually move.

That is why every apitegromab trial requires patients to already be on nusinersen or risdiplam. The drug is an add-on, not a replacement.

SAPPHIRE Phase 3 results

The trial was the bet that decided everything. SAPPHIRE (NCT05156320) ran from March 2022 to September 2024 across 48 hospitals in Belgium, France, Germany, Italy, Poland, Spain, the Netherlands, the UK, and the US.

Enrollment numbers: 188 patients total, including 156 in the primary age group (2 to 12 years) and 32 in an exploratory cohort (13 to 21 years).

Randomization in the 2-to-12 group was 1:1:1 to apitegromab 20 mg/kg, apitegromab 10 mg/kg, or placebo, all delivered IV every 4 weeks for 12 months.

The honest read is split. The combined-dose comparison was statistically positive, but the 20 mg/kg arm alone did not separate from placebo, which is why the FDA review will focus on the totality of evidence rather than one arm.

For context on how this compares to the broader category, see the anti-myostatin antibody overview.

How the dose is given

It is an in-clinic infusion. Apitegromab is delivered intravenously every 4 weeks at 10 mg/kg or 20 mg/kg, depending on age band and trial protocol.

The infusion is given on top of existing SMA therapy. Patients on nusinersen continue their intrathecal schedule, and patients on risdiplam continue their daily oral dose.

Steady-state plasma levels build over the first few infusions, which is why motor function changes in TOPAZ took roughly 6 to 12 months to emerge clearly.

There is no home injection version. Subcutaneous formulations are an active area of work in the antibody field, but apitegromab has not been validated outside the IV route.

TOPAZ long-term data

The Phase 2 data gave Scholar Rock the confidence to run SAPPHIRE. TOPAZ enrolled 58 children and young adults aged 2 to 21 with SMA Type 2 or Type 3, then followed them for years.

At 36 months, 35 nonambulatory patients had a mean HFMSE change of +4.0 points from baseline, and the 2-to-12 subgroup gained +4.8 points. Six children aged 2 to 12 at baseline gained new motor milestones, and two reached independent walking.

That is unusual for a population that typically loses function over time.

Long-term safety stayed clean. The most common events at 36 months were pyrexia (49%), nasopharyngitis (46%), and COVID-19 infections (40%), with no serious drug-related adverse events and no anti-drug antibodies.

Side effects in the real population

The safety profile looks like the SMA population, not the drug. In SAPPHIRE, the most frequent adverse events in apitegromab patients were:

• Pyrexia: 26% (vs 28% placebo)
• Nasopharyngitis: 25% (vs 23% placebo)
• Cough: 23% (vs 20% placebo)
• Vomiting: 23% (vs 17% placebo)
• Upper respiratory infection: 22% (vs 30% placebo)
• Headache: 21% (vs 20% placebo)

What is missing matters more. There were no signal events of epistaxis, telangiectasia, or gum bleeding, which were dose-limiting for ACE-031 in Duchenne. Targeting latent myostatin instead of the ActRIIB receptor avoids the BMP9/10 collateral damage.

FDA review timeline

The path was bumpier than the trial. Scholar Rock submitted a BLA in 2024 based on SAPPHIRE and TOPAZ, but the FDA issued a Complete Response Letter citing inspection findings at the Catalent Indiana fill-finish facility, not at any data quality issue.

The CRL was a manufacturing problem, not a drug problem. Scholar Rock added a second US fill-finish facility, addressed the Catalent observations in coordination with the FDA, and resubmitted.

In 2026, the FDA accepted the resubmitted BLA with a PDUFA target action date of September 30, 2026.

The drug also carries Fast Track designation, Rare Pediatric Disease designation, and Orphan Drug status in the US, plus PRIME and orphan designations in the EU.

How apitegromab compares to other myostatin drugs

It learned from a graveyard of failures. The original wave of myostatin inhibitors targeted the ActRIIB receptor or the active protein, and most failed.

The selective latent-myostatin angle is what makes apitegromab different. It is the first time a myostatin program has hit a Phase 3 primary endpoint in a muscle-wasting condition.

Who it actually fits

The label, if approved, will be narrow. SAPPHIRE enrolled nonambulatory SMA Type 2 or Type 3 patients aged 2 to 21 who had been on nusinersen for at least 10 months or risdiplam for at least 6 months, with baseline HFMSE scores between 10 and 45.

That defines the fit:

1. Already on an SMN therapy with stable dosing
2. Sits independently but does not walk independently
3. Motor function is well below age peers
4. Pediatric or young-adult age range
5. No current evidence to support use outside SMA

The drug is not a muscle-growth tool for healthy adults. The mechanism is interesting for sarcopenia and other muscle-wasting indications, but Scholar Rock has not run those trials.

For the broader category, see the myostatin inhibitor drug overview.

What costs and access will look like

The price has not been set publicly. SMA therapies sit in the high-orphan band: nusinersen lists around $750,000 in year one and $375,000 per year after, and onasemnogene abeparvovec lists at $2.1 million.

Apitegromab will likely land in a similar range, with year-one and ongoing costs that require commercial or specialty insurance coverage, prior authorization, and SMA Center of Excellence administration. Patient assistance programs from Scholar Rock will matter.

What is still unknown

The drug answered the big questions. It still has open ones.

• Whether the HFMSE gain translates to durable functional milestones beyond 12 months in the broader Phase 3 cohort
• How much of the benefit transfers to ambulatory SMA patients, not just nonambulatory
• Whether the mechanism helps adults with sarcopenia, Duchenne, or other muscle-wasting conditions
• Long-term tolerability beyond 4 years of dosing
• Whether a subcutaneous formulation is feasible

The Eli Lilly collaboration on obesity programs that some outlets referenced applies to other Scholar Rock molecules in muscle preservation during GLP-1 weight loss, not to apitegromab specifically. For that angle, see myostatin and GLP-1 muscle loss.

Sources and notes

This article was built from DuckDuckGo and Bing SERP review, full-page competitor reads, and primary sources:

• SAPPHIRE Phase 3 trial, Lancet Neurology 2025
• Apitegromab Wikipedia entry
• Scholar Rock SMA pipeline page
• Cure SMA: FDA accepts BLA for apitegromab
• TOPAZ 36-month follow-up, Frontiers in Neurology 2024
• SMA News Today apitegromab profile
• TOPAZ Phase 2 Neurology 2024

Frequently Asked Questions